Biotech Events And Company Events
The Fifth Session of U.S. Pharmacopeial Bioassay Convention
Why This convention will gather Biopharmaceutical/biotechnology industry professionals, Biopharmaceutical development scientists, Pharmaceutical industry professionals, Regulatory experts for biologics, Biosimilar manufacturers, Bioassay practitioners and software experts, Biostatisticians,
The Global Trial Site Database Brings into J&J, Merck, Lilly
The R&D is stepping closer to globalization, for example, recently J&J, Merck and Eli Lilly, the three pharma giants, is reportedly begun to create a "one-stop" database to help streamline their work with clinical trial sites worldwide. The objective of their action is to collect
The First Meningitis B Vaccine Is Believed to Be Soon Launched in Market
Bexsero of Navarits Meningitidis group B, a main strain of brain disease, attacks the lining of the brain and spinal cord. Parents are scared by it since it mainly threatens infants, as well as adults. It affects up to 40% of cases in North America and 80% in parts of Europe, according to the
Worldwide Biotech/Biopharma Alliance (From Nov. 12 to Otc. 30, 2012)
On Nov. 12, 2012, Caris Life Sciences Enhances Molecular Profiling Service With Addition of ROS1 and MGMT-Methylation Biomarkers. These markers are believed to serve as clinically-important aids in the development of treatment plans for patients with non-small cell lung cancer (NSCLC) and
Worldwide Biotech/Biopharma Executives (From Nov. 7 to Nov. 2, 2012)
On Nov. 7, 2012, Array BioPharma Inc. announced John A. Orwin, chief executive officer of Affymax, Inc., joined the Company's board of directors. On Nov. 6, 2012, Apricus Biosciences, Inc. ("Apricus Bio" or the "Company") (APRI) announced that Bassam Damaj, Ph.D., has resigned as a Director,
The New Diabetes Drug of Novo Nordisk A/S (NVO) Get Approval by FDA
Novo Nordisk is a global healthcare company with 89 years of innovation and leadership in diabetes care. On Nov. 8, 2012, the Endocrinologic and Metabolic Drugs Advisory Committee of the United States Food and Drug Administration (FDA) completed the New Drug Application (NDA) for insulin
Start to Register for the 2013 BIO International Convention
Introduction In 1993, BIO held its first International Convention, which at that time drew 1,400 representatives. While in 2007, it drew 22,000 representatives. The keynote speakers are also quite expecting for attendees, top bio enterprises, research institutions, public agencies and so
The 2nd Novel Immunotherapeutics Summit of GTC
Why Experts from academia and industry to discuss cutting edge research, immuno-strategies and novel findings and therapeutics against various diseases. Representatives from top leaders in the pharmaceutical and biotech industries including Abbott, Bristol-Myer-Squibbs, Johnson &
The 4th Annual Next Generation Sequencing Congress in 2012
Where senior practitioners both of academia and pharma would gather together Why Over 350 experts from both academia and pharma senior practitioners engaged in kinds of next generation sequencing including personalized healthcare/clinical/diagnostic development, genomics, epigenetics, DNA
Amgen Webcast Investor Meeting at Upcoming American Heart Association
Now one of our industry peers—Amgen, according to the Market Capitalization in Q2 of 2012 rank, is the top 2/25 biotechnology companies, the world largest independent biotechnology firm, On Nov. 1, announced it will host a webcast investor meeting at the American Heart Association (AHA)
Partnership between EMD Milipore and Systemic on Control Markers for Stem Cell
On the second annual Stem Cell Meeting on the Mesa, EMD Millipore and Systemic Ltd. declaimed becoming partners to identify control markers for stem cell production. EMD Millipore, the life science division of Merck KGaA of Germany. It is expertise of stem cells. Systemic Ltd, a leading provider